Double cord blood transplant with abatacept for GVHD prevention
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding abatacept to a double cord blood transplant can prevent graft-versus-host disease (GVHD) in people with certain blood cancers. You may qualify if you have high-risk leukemia or other blood disorders and do not have a matched related or unrelated donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 70 years old.
- You must have one of these blood cancers: AML, ALL, MDS, mixed-phenotype leukemia, CML in second chronic phase, CMML, or relapsed Hodgkin lymphoma.
- You must be in complete remission or have low blast counts in the marrow (less than 10%) if you have active leukemia.
- You must not have a suitable matched related or unrelated donor, but you are eligible for a double cord blood transplant.
- You must have good enough heart, lung, liver, and kidney function, as determined by specific tests.
- You cannot be pregnant or breastfeeding, and must agree to strict contraception if you are of childbearing potential.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to do a stem cell transplant for people with hard-to-treat blood cancers. It combines a half-matched family donor (haploidentical) with a cord blood unit to help the transplant work better.
This study tests whether using cord blood stem cells (collected from umbilical cords after birth) can help treat high-risk blood cancers in children and young adults when a matched donor is not quickly available. Cord blood transplants may help prevent cancer from coming back.
This trial studies transplanting healthy blood-forming cells from an umbilical cord blood donor who is not related to you. It may help people with certain blood cancers, immune disorders, or other serious diseases when a standard transplant plan is needed.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This trial tests a two-step use of ATG (a drug that calms immune cells) to help prevent graft-versus-host disease (GVHD) in patients receiving a stem cell transplant from a donor. It may be an option for people with certain blood cancers or disorders who are getting a strong, marrow-clearing transplant.
This trial tests whether adding abatacept to standard care can reduce graft-versus-host disease (a condition where donor cells attack your body) after a stem cell transplant using a special cord blood product called omidubicel. It is for adults with blood cancers who have a suitable cord blood unit available.
Hear when a new Chronic Myelogenous Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.